Ticagrelor

Drug Profile

Ticagrelor

Alternative Names: AR-C 126532; AZD-6140; Brilinta; Brilique

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; The Medicines Company; Uppsala University; Vanderbilt University
  • Class Antithrombotics; Cyclopropanes; Fluorobenzenes; Purine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes
  • Phase III Cardiovascular disorders; Stroke
  • Phase II Abdominal aortic aneurysm; Community-acquired pneumonia; Coronary artery disease; Sickle cell anaemia
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 27 Feb 2017 AstraZeneca completes a phase II trial in Sickle cell anaemia (In children, In adolescents) in USA, Canada, Kenya, Lebanon, Italy, South Africa and the United Kingdom (NCT02214121)
  • 01 Nov 2016 AstraZeneca completes the Hestia2 trial in Sickle cell anaemia (In adults) in USA, Egypt, France, Italy, Kenya, Lebanon, Turkey and United Kingdom (NCT02482298)
  • 30 Sep 2016 Discontinued - Phase-III for Peripheral arterial disorders in Sweden, Germany, Poland, Poland, Netherlands, United Kingdom, Hungary, Spain, Czech Republic, Bulgaria, France, Argentina, Brazil, Canada, Chile, China, Japan, Vietnam, Ukraine, Thailand, Turkey, Slovakia, Russia, Philippines, Mexico, South Korea, USA, Italy, Romania (PO) before September 2016 as the trial did not meet its primary endpoint (AstraZeneca pipeline, November 2016; AstraZeneca Third quarter results, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top